IPO Trending
CONCORDBIOEQ / NSE, BSEListed

Concord Biotech Limited

Incorporated in 1984, Concord Biotech Limited is an India-based biopharmaceutical company and a leading global developer and manufacturer of fermentation-based APIs, specializing in immunosuppressants and oncology. The company has a strong global presence, supplying products to over 70 countries including the USA, India, Europe, and Japan. Concord Biotech manufactures Active Pharmaceutical Ingredients (APIs) through fermentation and semi-synthetic processes, along with finished formulations. Starting with a single product, the company has expanded to offer a broad spectrum of biopharma solutions, establishing itself as a key player in the global API market.

₹705 - ₹74126.13x sub
Listed Price900.05
Listing Gain+21.46%
Review-Analyst Consensus Verdict

May apply

No review summary is available yet.

Apply
00%
May Apply
00%
Neutral
00%
Avoid
00%
Not Rated
00%
No IPO review records are available for this issue yet.